Evaluation of Finastride Effect in Different Dosage on the Amount of Perioperative Bleeding in Transurthral Resection of Prostate

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01627522

Acronym

TURP

Enrollment

Registered

2012-06-25

Start date

2012-01-31

Completion date

2013-05-31

Last updated

2016-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostate Hyperplasia

Brief summary

Preoperative use of finastride will decrease the amount of perioperative blood loss during and after TURP The effect of finastride on decreasing the amount of perioperative blood loss during and after TURP is dose dependent Finastride will decrease microvascular density in prostate tissue and this effect is dose dependent

Interventions

PROCEDURETURP

Transurthral resection of prostate

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

MALE

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with BPH that require TURP

Exclusion criteria

* Previous prostate surgery * Prostate Cancer * Coagulopathy * The use of NSAIDs, Anticoagulants, Antiplatelet drugs * CRF/ESRD

Design outcomes

Primary

Measure	Time frame
Perioperative Hb Drop	24 hours after surgery

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026